ARGENX Receives FDA Priority Review for VYVGART sBLA in Seronegative gMG, Targeting Expanded Patient Population

summarizeResume

The FDA's acceptance of the supplemental Biologics License Application (sBLA) for VYVGART with Priority Review is a significant positive development for ARGENX. This accelerates the potential approval timeline for an expanded indication, addressing a critical unmet medical need in acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG) patients. The positive Phase 3 ADAPT SERON study data supporting the sBLA further de-risks the approval process and positions VYVGART to capture a broader market segment, potentially driving future revenue growth for the company.

check_boxEvenements cles

• FDA Accepts sBLA with Priority Review

  The U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART (efgartigimod alfa-fcab) for the treatment of adults with AChR-Ab seronegative generalized myasthenia gravis (gMG).

• PDUFA Target Action Date Set

  A Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026, has been set for the sBLA.

• Supported by Positive Phase 3 Data

  The sBLA is supported by data from the Phase 3 ADAPT SERON study, which met its primary endpoint, demonstrating statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score compared to placebo.

• Addresses Unmet Medical Need

  This expanded indication aims to provide a much-needed treatment option for seronegative gMG patients, who currently face limited therapeutic choices.

auto_awesomeAnalyse

The FDA's acceptance of the supplemental Biologics License Application (sBLA) for VYVGART with Priority Review is a significant positive development for ARGENX. This accelerates the potential approval timeline for an expanded indication, addressing a critical unmet medical need in acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG) patients. The positive Phase 3 ADAPT SERON study data supporting the sBLA further de-risks the approval process and positions VYVGART to capture a broader market segment, potentially driving future revenue growth for the company.